Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drug

Plus, news about Merus, Supernus and Verrica:

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FTC says pharmacy benefit managers are stonewalling requests for information

A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents

February 27, 2024

Exclusive: mRNA CDMO Vernal Biosciences secures $20M to continue its buildout

Vermont may be known for maple syrup and Ben & Jerry’s ice cream, but one manufacturer wants the Green Mountain State to become a producer

June 15, 2023

Taking stock of the frenzied push into autoimmune disease

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday

April 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.